428 related articles for article (PubMed ID: 21852502)
21. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
Ishihara J; Ishihara A; Potin L; Hosseinchi P; Fukunaga K; Damo M; Gajewski TF; Swartz MA; Hubbell JA
Mol Cancer Ther; 2018 Nov; 17(11):2399-2411. PubMed ID: 30097487
[TBL] [Abstract][Full Text] [Related]
22. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.
Horton HM; Bernett MJ; Peipp M; Pong E; Karki S; Chu SY; Richards JO; Chen H; Repp R; Desjarlais JR; Zhukovsky EA
Blood; 2010 Oct; 116(16):3004-12. PubMed ID: 20616215
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody.
Chen W; Yu Y; Shao C; Zhang M; Wang W; Zhang L; Cao X
Immunol Lett; 2001 May; 77(1):17-23. PubMed ID: 11348665
[TBL] [Abstract][Full Text] [Related]
24. Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties.
Ceglia V; Zurawski S; Montes M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
J Immunol; 2021 Oct; 207(8):2060-2076. PubMed ID: 34551965
[TBL] [Abstract][Full Text] [Related]
25. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
[TBL] [Abstract][Full Text] [Related]
26. A general Fc engineering platform for the next generation of antibody therapeutics.
Chen D; Zhao Y; Li M; Shang H; Li N; Li F; Wang W; Wang Y; Jin R; Liu S; Li X; Gao S; Tian Y; Li R; Li H; Zhang Y; Du M; Cao Y; Zhang Y; Li X; Huang Y; Hu LA; Li F; Zhang H
Theranostics; 2021; 11(4):1901-1917. PubMed ID: 33408788
[No Abstract] [Full Text] [Related]
27. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.
Chu SY; Vostiar I; Karki S; Moore GL; Lazar GA; Pong E; Joyce PF; Szymkowski DE; Desjarlais JR
Mol Immunol; 2008 Sep; 45(15):3926-33. PubMed ID: 18691763
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
29. Suppression of IL-4- and CD40-induced B-lymphocyte activation by intravenous immunoglobulin is not mediated through the inhibitory IgG receptor FcgammaRIIb.
Zhuang Q; Bisotto S; Fixman ED; Mazer B
J Allergy Clin Immunol; 2002 Sep; 110(3):480-3. PubMed ID: 12209098
[TBL] [Abstract][Full Text] [Related]
30. IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.
Lee CH; Romain G; Yan W; Watanabe M; Charab W; Todorova B; Lee J; Triplett K; Donkor M; Lungu OI; Lux A; Marshall N; Lindorfer MA; Goff OR; Balbino B; Kang TH; Tanno H; Delidakis G; Alford C; Taylor RP; Nimmerjahn F; Varadarajan N; Bruhns P; Zhang YJ; Georgiou G
Nat Immunol; 2017 Aug; 18(8):889-898. PubMed ID: 28604720
[TBL] [Abstract][Full Text] [Related]
31. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma.
Honeychurch J; Glennie MJ; Johnson PW; Illidge TM
Blood; 2003 Aug; 102(4):1449-57. PubMed ID: 12714523
[TBL] [Abstract][Full Text] [Related]
32. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Bulliard Y; Jolicoeur R; Windman M; Rue SM; Ettenberg S; Knee DA; Wilson NS; Dranoff G; Brogdon JL
J Exp Med; 2013 Aug; 210(9):1685-93. PubMed ID: 23897982
[TBL] [Abstract][Full Text] [Related]
33. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.
Funakoshi S; Longo DL; Murphy WJ
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):93-101. PubMed ID: 8732692
[TBL] [Abstract][Full Text] [Related]
34. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application.
Filbert EL; Björck PK; Srivastava MK; Bahjat FR; Yang X
Cancer Immunol Immunother; 2021 Jul; 70(7):1853-1865. PubMed ID: 33392713
[TBL] [Abstract][Full Text] [Related]
35. Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activity.
Chenoweth AM; Esparon S; Wines BD; Schuurman J; Labrijn AF; Hogarth PM
Immunol Cell Biol; 2023 Aug; 101(7):657-662. PubMed ID: 36997299
[TBL] [Abstract][Full Text] [Related]
36. Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs.
Taraban VY; Rowley TF; Al-Shamkhani A
J Immunol; 2004 Dec; 173(11):6542-6. PubMed ID: 15557144
[TBL] [Abstract][Full Text] [Related]
37. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells.
Lefrançois L; Altman JD; Williams K; Olson S
J Immunol; 2000 Jan; 164(2):725-32. PubMed ID: 10623816
[TBL] [Abstract][Full Text] [Related]
38. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody.
Chu SY; Horton HM; Pong E; Leung IW; Chen H; Nguyen DH; Bautista C; Muchhal US; Bernett MJ; Moore GL; Szymkowski DE; Desjarlais JR
J Allergy Clin Immunol; 2012 Apr; 129(4):1102-15. PubMed ID: 22257644
[TBL] [Abstract][Full Text] [Related]
39. Anti-FcγRIIB (CD32) Antibodies Differentially Modulate Murine FVIII-Specific Recall Response in vitro.
Vollack N; Friese J; Bergmann S; Cragg MS; Tiede A; Werwitzke S
Scand J Immunol; 2017 Aug; 86(2):91-99. PubMed ID: 28561280
[TBL] [Abstract][Full Text] [Related]
40. The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII(-/-) mice.
Sallin MA; Zhang X; So EC; Burch E; Cai L; Lin W; Chapoval AI; Strome SE
Cancer Immunol Immunother; 2014 Sep; 63(9):947-58. PubMed ID: 24927849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
